Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2

Yosipovitch, Gil; Gooderham, Melinda J.; Ständer, Sonja; Fonacier, Luz; Szepietowski, Jacek C.; Deleuran, Mette; Girolomoni, Giampiero; Su, John C.; Bushmakin, Andrew G.; Cappelleri, Joseph C.; Feeney, Claire; Chan, Gary; Thorpe, Andrew J.; Valdez, Hernan; Biswas, Pinaki; Rojo, Ricardo; DiBonaventura, Marco; Myers, Daniela E.

doi:10.1007/s40257-023-00810-7

Cited by 5 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Эти селективные иммуносупрессоры показали высокую эффективность в отношении быстрого уменьшения выраженности клинических проявлений поражения кожи и контроля зуда. Благоприятный профиль «польза/риск» этих препаратов в качестве монотерапии и в комбинации с другими методами лечения был подтвержден в различных крупных рандомизированных клинических исследованиях с высоким уровнем достоверности, таких как Measure Up 1 и 2, AD Up для упадацитиниба [28,29], BREEZE-AD1, BREEZE-AD2, BREEZE-AD7, BREEZE-AD4 для барицитиниба [30,31], JADE MONO-1 и MONO-2, JADE TEEN, JADE COMPARE, JADE DARE и JADE REGIMEN для аброцитиниба [32][33][34][35]. Аброцитиниб является единственным представителем JAK-ингибиторов, который был разработан именно для лечения АтД и прошел крупномасштабную программу клинических исследований с участием более 3850 взрослых и подростков.…”

Section: Dermal Diseasesunclassified

JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice

Potekaev,

Tereshchenko,

Gadzhigoroeva

2024

Medicinskij sovet

View full text Add to dashboard Cite

Atopic dermatitis (AtD) is currently considered as a systemic disease due to the fact, that disorders of innate and adaptive immune response, especially pronounced in severe course, are manifested not only in skin inflammation, but also can be realized in the development of other chronic diseases, including autoimmune profile. One of the autoimmune comorbid diseases in AtD is alopecia areata (AA), which is confirmed by epidemiologic data, clinical features and identification of common immune links of pathogenesis in the case of association of these diseases. Janus-kinase inhibitors, which represent a new class of targeted synthetic basic anti-inflammatory drugs, are currently the main pathogenetic treatments for severe forms of AtD and AA. Acting on several immune axes, these drugs selectively and reversibly modulate the signaling activity of key inflammatory cytokines, which makes them the most promising strategy for systemic therapy of these dermatoses, including in cases of their combination. The article covers the review of pathophysiology and application of first and second generation JAK-inhibitors in AtD and AA, including the analysis of their efficacy in the simultaneous presence of these pathological conditions. We present own observations of two patients with severe comorbid conditions AtD and AA, treated with the JAK-inhibitors abrocitinib and upadacitinib. These examples confirm the efficacy of Janus-kinase inhibitors in AtD and AA in real clinical practice and describe the experience of switching from one JAK-inhibitor of the first generation to another, selective JAK-inhibitor, as well as the effect of of these drugs on the course of both pathologies. Taking into account the necessity of long-term use of JAK-inhibitors, further study of their long-term efficacy and safety remains relevant.

show abstract

Section: Dermal Diseasesunclassified

JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice

Potekaev,

Tereshchenko,

Gadzhigoroeva

2024

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

“…However, it remains unclear whether neuropsychiatric comorbidities in AD result from persistent and intense itching, poor sleep, and stigma, or if they are direct consequences of proinflammatory cytokines generated by AD inflammation and accelerated neuroinflammation [ 7 , 15 ]. The contributory role of sleep disturbance and itch in the development of AD psychosocial complications has been studied, but the roles of psychological, neurological, and molecular factors are, to date, largely unquantified [ 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

The Psychology of Atopic Dermatitis

Courtney,

2024

JCM

Self Cite

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common chronic inflammatory skin condition characterised by pruritus and recurrent eczematous patches and plaques. It impacts sleep and its visibility can lead to stigmatisation, low self-esteem, social withdrawal, reduced quality of life (QOL), and psychological burden. This study explores the relationship between AD and mental health, including possible causation pathways. A literature review was conducted in PubMed without using limiters. AD carries higher odds of suicidality and an increased risk of depression, anxiety, alexithymia, and obsessive–compulsive disorder (OCD) across all severities. While some studies report an association of AD with attention deficit hyperactivity disorder (ADHD), and possibly autism spectrum disorder (ASD), others do not. There is increasing evidence that AD contributes to chronic low-grade inflammation and cognitive impairment (CI). Causative factors for mental health complications of AD likely include both psychosocial and biological variables. AD is associated with higher levels of cutaneous and circulating proinflammatory cytokines; these can breach the blood–brain barrier and trigger central nervous system events, including oxidative stress, neurotransmitter breakdown, altered serotonin metabolism, and reduced neurogenesis in several brain regions. Excessive inflammation in AD may thus contribute to CI, depression, and suicidality. AD providers should be vigilant about mental health.

show abstract

Januskinaseinhibitoren für dermatologische Erkrankungen

Solimani,

Ghoreschi

2024

Dermatologie

View full text Add to dashboard Cite

Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2

Cited by 5 publications

References 38 publications

JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice

JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice

The Psychology of Atopic Dermatitis

Januskinaseinhibitoren für dermatologische Erkrankungen

Contact Info

Product

Resources

About